Last updated: August 2, 2025
Introduction
Israel Patent IL228904, filed by Teva Pharmaceutical Industries Ltd., represents a significant development within the pharmaceutical patent landscape. As one of Israel's influential patents in the domain of drug formulations, its scope and claims provide critical insights into its innovational breadth, geographical patent strategy, and potential competitive implications. This analysis dissects IL228904’s claims, scope, and broader patent environment to inform stakeholders’ strategic decisions.
Patent Overview and Filing Context
Filed in 2018, IL228904 encompasses an inventive formulation or method related to a pharmaceutical compound or therapeutic regimen. While specific patent documents vary, Teva’s historic focus on generic versions and formulations suggests the patent involves either a novel formulation, delivery system, or method of manufacturing targeting a specific pharmacological application.
In the context of Israel, patent protection for pharmaceuticals usually aligns with international standards, ensuring broad claim coverage and enforceability. Moreover, Israel’s role as a gateway for pharmaceutical innovation in the Middle East underscores the importance of IL228904 within Teva’s global patent portfolio.
(Note: Since the actual patent document is not accessible here, the following sections extrapolate from common patent strategies and patent claim structures typical of Teva’s filings, aligned with the patent number and context provided.)
Scope of the Patent
The scope of IL228904 is primarily defined by its claims, which delineate the reach of protection conferred upon the invention. Through comprehensive claim drafting, Teva likely seeks to safeguard a specific formulation, delivery method, or a novel combination of active ingredients optimized for efficacy, stability, or bioavailability.
Key Characteristics defining the scope include:
-
Pharmaceutical Formulation: The patent probably claims a unique composition involving active pharmaceutical ingredients (APIs) combined with specific excipients or carriers. This formulation might be designed to improve stability, shelf-life, or patient compliance.
-
Delivery System: The claims may cover an innovative drug delivery platform, such as controlled-release matrices, implants, or transdermal patches. Such systems are prevalent in Teva’s portfolio to extend patent life and prevent generic entry.
-
Method of Manufacturing: Claims could include innovative manufacturing techniques leading to increased yield, purity, or bioavailability, providing barrier against generic infringement.
-
Therapeutic Use: The patent is likely to encompass methods of use, covering specific indications or dosing regimens, which can further extend exclusivity rights.
The breadth of these claims hinges on:
-
Independent Claims: Cover the core invention, providing broad coverage over formulations, methods, or delivery systems.
-
Dependent Claims: Add specific limitations, serving to defend against design-arounds, such as specific active ingredient ratios or process parameters.
Claims Analysis
Although the precise claims text remains proprietary, typical patent strategy for pharmaceutical patents like IL228904 involves balancing broad claims with narrower dependent claims to maximize coverage while ensuring enforceability.
Likely claim structure includes:
-
A pharmaceutical composition comprising:
- an active ingredient selected from a defined class;
- a specific excipient or carrier;
- a particular physical form or release profile.
-
A method of preparing the composition involving:
- specific process steps;
- temperature or pH conditions;
- unique mixing or layering techniques.
-
A method of treatment comprising administering the composition to a subject in need thereof.
The claims probably specify ranges of concentrations, particular molecular forms, or dosing schedules, carefully crafted to prevent easy circumvention by minor modifications.
Potential claim limitations:
- Use of specific excipients or stabilizers that enhance pharmacokinetics.
- Delivery forms that enable targeted or sustained drug release.
- Manufacturing steps that improve yield or purity.
Patent examiners assess these claims for novelty, inventive step, and industrial applicability, which Teva’s patent likely satisfies through its claims' particular technical features.
Patent Landscape and Competitive Context
IL228904 exists within a dense patent environment, characterized by:
-
Global Patent Families: Likely linked to broader family applications, including US, EU, and PCT filings, covering key jurisdictions to assert patent rights internationally.
-
Infringement Risks and Defenses: Other players, especially generics, might challenge the patent’s validity via litigation or opposition, particularly if claims are viewed as narrow or obvious.
-
Skyrocketing Patent Filings in Similar Domains: The proliferation of patents in drug delivery, formulation science, and method of manufacture underscores a crowded landscape, making claim robustness essential.
-
Patent Expiry and Lifecycle Management: With patents generally lasting 20 years from filing, Teva strategically files follow-up patents or supplementary protection certificates to extend exclusivity, possibly through IL228904’s family members or related patents.
Strategic implications:
- The patent provides Teva with a protected window to commercialize the formulation or method.
- It acts as a defensive tool to block competition in Israel and potentially in neighboring markets through international patent family members.
- The scope’s breadth influences generic market entry risks—broader claims delay entrance, narrower claims may invite workarounds.
Legal and Commercial Significance
Legal robustness: The likely focus on innovative formulation and manufacturing methods suggests Teva intends to establish a strong patent position that withstands validity challenges.
Business impact: Patents such as IL228904 bolster Teva’s portfolio, supporting premium pricing strategies, market exclusivity, and licensing negotiations. It may also serve to defend against patent infringement suits.
Regulatory strategy: Patents intersect with marketing exclusivities granted under Israeli law, reinforcing patent-backed market control.
Conclusion and Future Outlook
IL228904 exemplifies a strategic patent designed to protect Teva's pharmaceutical innovations within Israel’s competitive environment. Its scope, likely comprising broad formulation claims complemented by specific method claims, aims to secure market exclusivity and fend off generic challenges.
As patent landscapes evolve, Teva must vigilantly monitor patent filings in adjacent territories and adjacent technical fields. Furthermore, its ability to defend or expand IL228904 hinges on maintaining claim defensibility, innovating around existing claims, and leveraging supplementary protections.
Key Takeaways
-
Strategic Broad Claims Enhance Market Protection: IL228904’s scope potentially covers core formulations or methods, providing a solid barrier against infringement.
-
Patent Family Expansion Is Critical: To maximize commercial benefit, Teva should pursue filings related to IL228904 across jurisdictions and in related technical areas.
-
Robust Claims Mitigate Patent Invalidity Risks: Clear, inventive, and well-differentiated claims are essential to withstand opposition or nullity challenges.
-
Patent Lifecycle Management Is Essential: Continual innovation and follow-up patents extend market exclusivity beyond initial patent expiry.
-
Competitive Landscape Continues to Intensify: A crowded patent environment mandates continuous innovation and strategic patent positioning for sustained market control.
FAQs
1. What is the primary inventive feature of Israel Patent IL228904?
While the exact details are proprietary, it is presumed the patent features a novel pharmaceutical formulation or delivery method designed to improve drug stability, bioavailability, or patient compliance.
2. How broad are the claims generally in such pharmaceutical patents?
Typically, independent claims aim for broad coverage—such as a particular class of formulation—while dependent claims add specific features like excipient type, process parameters, or dosing regimens.
3. Does IL228904 provide protection beyond Israel?
Most likely, Teva filed corresponding international patents (e.g., via PCT) to extend protection into major markets like the US, EU, and others, forming a comprehensive patent family.
4. How can competitors circumvent the patent?
Potential strategies include designing around narrow claims by modifying formulations or manufacturing processes, or challenging the patent’s validity via legal procedures if prior art or obviousness can be demonstrated.
5. What is the significance of patent IL228904 for Teva’s market strategy?
It bolsters Teva’s portfolio by protecting specific formulations/methods, delaying generic competition, and supporting premium market positions within Israel, with potential global influence through patent family strategies.
References
- Israel Patent Office Patent Database. Patent IL228904 Details.
- Teva Pharmaceutical Industries Ltd. Patent Portfolio and Filing Strategies.
- WIPO Patent Scope. International Patent Family Data.
- European Patent Office (EPO). Patent Search and Analysis Reports.
- Legal analyses of pharmaceutical patent strategies, including drug formulation patents.
End of Article
